Completeness of reporting scores for each CARE topic and question (11)
| Topic | Item | Question | Mean COR per item ± SD, % |
|---|---|---|---|
| Title | 1 | The words “case report” should be in the title along with what is of greatest interest in this case | 20 ± 2.5 |
| Keywords | 2 | The key elements of this case in 2–5 keywords | 37 ± 0.0 |
| Abstract | 3a | Introduction: What is unique about this case? What does it add to the medical literature? | 41 ± 1.8 |
| 3b | The main symptoms of the patient and the important clinical findings | 31 ± 2.9 | |
| 3c | The main diagnoses, therapeutics interventions and outcomes | 38 ± 0.7 | |
| 3d | Conclusion: What were the main “take-away” lessons from this case? | 39 ± 0.4 | |
| Introduction | 4 | Brief background summary of this case referencing the relevant medical literature | 72 ± 2.5 |
| Patient information | 5a | Demographic information (e.g., age, gender, ethnicity and occupation) | 99 ± 0.4 |
| 5b | Main symptoms of the patient (chief complaints) | 96 ± 1.4 | |
| 5c | Medical, family and psychosocial history, including comorbidities and relevant genetic information | 69 ± 1.1 | |
| 5d | Relevant past interventions and their outcomes | 42 ± 6.9 | |
| Clinical findings | 6 | Describe the relevant PE findings | 76 ± 0.7 |
| Timeline | 7 | Depict important milestones related to the diagnoses and interventions (table or figure) | 41 ± 8.3 |
| Diagnostic assessment | 8a | Diagnostic methods (e.g., PE, laboratory testing, imaging and questionnaires) | 98 ± 0.4 |
| 8b | Diagnostic challenges (e.g., financial, language and cultural) | 13 ± 0.4 | |
| 8c | Diagnostic reasoning, including other diagnoses considered | 76 ± 25.0 | |
| 8d | Prognostic characteristics (e.g., staging in oncology) where applicable | 14 ± 6.9 | |
| Therapeutic intervention | 9a | Types of intervention (e.g., pharmacologic, surgical, preventive and self-care) | 84 ± 2.2 |
| 9b | Administration of intervention (e.g., dosage, strength and duration) | 53 ± 9.7 | |
| 9c | Changes in intervention (with rationale) | 53 ± 11.0 | |
| Follow-up and outcomes | 10a | Clinician-assessed outcomes and, when appropriate, patient-assessed outcomes | 71 ± 2.2 |
| 10b | Important follow-up test results | 71 ± 12.0 | |
| 10c | Intervention adherence and tolerability (how was this assessed?) | 16 ± 14.0 | |
| 10d | Adverse and unanticipated events | 22 ± 10.4 | |
| Discussion | 11a | Discussion of the strengths and limitations in the management of this case | 45 ± 0.7 |
| 11b | Discussion of the relevant medical literature | 82 ± 0.7 | |
| 11c | The rationale for conclusions (including assessment of possible causes) | 83 ± 4.3 | |
| 11d | The main “take-away” lessons of this case report | 88 ± 4.7 | |
| Patient perspective | 12 | Did the patient share his or her perspective or experience? (include when appropriate) | 1.8 ± 0.4 |
| Informed consent | 13 | Did the patient give informed consent? Please provide if requested | 33 ± 1.4 |
| Additional information | 14 | Acknowledgement section; competing interests; institutional review board approval when required | 84 ± 5.1 |
Note: CARE = Case Report statement and checklist, COR = completeness of reporting, PE = physical examination, SD = standard deviation.